Treating reactive arthritis: insights for the clinician
- 30 December 2009
- journal article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 2 (1) , 45-54
Abstract
There are two main forms of reactive arthritis (ReA): postvenereal and postdysentery. Chlamydia trachomatis (Ct) is the major causative organism of the postvenereal type; Salmonella, Shigella, Campylobacter, and Yersinia are the major triggers for the postenteric type. All of these causative organisms have been shown to traffic to the synovium in affected individuals. However, one important difference is that the chlamydial organisms have been shown to be viable, whereas, in general, the postenteric organisms are not. Although estimates vary widely, it is felt that 30-50% of all cases of ReA become chronic and the remainder resolve spontaneously within weeks to months. These important differences need to be considered when reviewing the available therapeutic outcomes data. There is a relative paucity of prospective clinical trial data assessing various treatment strategies. A large breadth of clinical experience demonstrates that nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are efficacious, but there have only been two rather small trials assessing NSAIDs and none with corticosteroids. Disease modifying drugs are sometimes utilized in more severe or chronic cases, but only sulfasalazine (SSZ) has been studied. Anti-tumor necrosis factor (TNF) therapy has proved remarkably efficacious with other types of spondyloarthritides, but there is very little data to support their use in ReA; theoretical concerns also exist with this drug class in ReA, specifically. Finally, antibiotics have been studied in several trials. A thorough analysis of these trials reveals equivocal results with a possible particular benefit in postchlamydial ReA. These data are reviewed with an emphasis on postchlamydial and postenteric ReA.Keywords
This publication has 57 references indexed in Scilit:
- Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritisArthritis & Rheumatism, 2009
- Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based studyAnnals of the Rheumatic Diseases, 2008
- Retraction of the suggestion to use the term “Reiter's syndrome” sixty‐five years later: The legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnationArthritis & Rheumatism, 2007
- Declining use of the eponym “Reiter's syndrome” in the medical literature, 1998–2003Journal of the American Academy of Dermatology, 2005
- Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trialArthritis & Rheumatism, 2005
- Alpha beta but not gamma delta T cell clones in synovial fluids of patients with reactive arthritis show active transcription of tumour necrosis factor α and interferon γAnnals of the Rheumatic Diseases, 2004
- Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trialAnnals of the Rheumatic Diseases, 1997
- Histopathology of intestinal inflammation related to reactive arthritis.Gut, 1987
- A Double-Blind Cross-Over Evaluation of Ketoprofen and Indomethacin in Reiter's DiseaseScandinavian Journal of Rheumatology, 1982
- A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's diseaseCurrent Medical Research and Opinion, 1976